An update in pulmonary hypertension in systemic lupus erythematosus - Do we need to know about it?

Lupus

Volumn 17, Issue 4, 2008, Pages 274-277

  Pope, Janet ^a  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Pulmonary arterial hypertension; Systemic lupus erythematosus

Indexed keywords

ADRENALIN; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; NIFEDIPINE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; SILDENAFIL; WARFARIN;

EARLY DIAGNOSIS; ELECTROCARDIOGRAM; EXERCISE TOLERANCE; FATIGUE; HEART CATHETERIZATION; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; LUNG COMPLICATION; LUNG FIBROSIS; MORTALITY; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULITIS; REVIEW; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM;

DIAGNOSIS, DIFFERENTIAL; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 43249099112     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307087188     Document Type: Review

References (19)

1. Proceedings of the third world symposium on pulmonary arterial hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol 2004; 43 (Suppl. S): 1S-90S.
2. Pope, JE, Lee, P, Baron, M, et al. Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 2005; 32: 1273-1278.
3. Sanchez, O, Sitbon, O, Garcia, G, Jais, X, Simonneau, G, Humbert, M. Pulmonary artery hypertension associated with connective tissue diseases. Presse Med 2003; 32: 789-799.
4. Haas, C. Pulmonary hypertension associated with systemic lupus erythematosus. Bull Acad Natl Med 2004; 188: 985-997.
5. Shen, JY, Chen, SL, Wu, YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18: 147-151.
6. Johnson, SR, Gladman, DD, Urowitz, MB, Ibanez, D, Granton, JT. Pulmonary hypertension in systemic lupus. Lupus 2004; 13: 506-509.
7. Arcasoy, SM, Christie, JD, Ferrari, VA, et al. Echokardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735-740.
8. Gonzalez-Lopez, L, Cardona-Munoz, EG, Celis, A, et al. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus 2004; 13: 105-112.
9. Pearson, JD. Normal endothelial cell function. Lupus 2000; 9: 183-188.
10. Matsuda, J, Tsukamoto, M, Gohchi, K, Saitoh, N, Miyajima, Y, Kazama, M. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon. Acta Haematol 1992; 88: 189-193.
11. Nakamura, T, Ebihara, I, Tomino, Y, Koide, H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995; 47: 481-489.
12. Yoshio, T, Masuyama, J, Mimori, A, et al. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995; 54: 361-365.
13. Chung, SM, Lee, CK, Lee, EY, Yoo, B, Lee, SD, Moon, HB. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension. Clin Rheumatol 2006; 25: 866-872 [Epub 22 Feb 2006].
14. Kim, WU, Min, JK, Lee, SH, Park, SH, Cho, CS, Kim, HY. Causes of death in Korean patients with systemic lupus erythematosus: a single center retrospective study. Clin Exp Rheumatol 1999; 5: 539-545.
15. Esdaile, JM, Abrahamowicz, M, Grodzicky, T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44: 2331-2337.
16. Houman, MH, Smiti-Khanfir, M, Ben Ghorbell, I, Miled, M. Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients. Lupus 2004; 13: 4-11.
17. Assous, N, Allanore, Y, Batteux, F, et al. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury. Clin Exp Rheumatol 2005; 23: 199-204.
18. Rich, S, Kaufmann, E, Levy, PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
19. Denton, CP, Gabrielli, A, Peter, HH, Morganti, A, Pope, J, Guillevin, L. Long-term effects of Bosentan treatment on survival in patients with pulmonary arterial hypertension related to connective tissue disease (PAH-CTD): the TRUST study results. Arthritis Rheum 2006; 54 (Suppl.): S740 [Abstract].